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Available online 26 June 2016Background: Growing evidence suggests a possible association between low vitamin D levels and increased car-
diovascular risk. However, research regarding the period of adolescence is scarce. We aimed to evaluate the as-
sociation of vitamin D, intake and serum 25(OH)D levels, with cardiometabolic risk factors in 13-year-old
adolescents.
Methods:We conducted a cross-sectional analysis of 1033 adolescents evaluated at 13 years old as part of the
population-based cohort EPITeen. Vitamin D intake was assessed by a food frequency questionnaire. Serum
25(OH)D levelswere assessed for a subsample of 514 participants.Metabolic syndrome (MetS) featureswere de-
ﬁned according to the National Cholesterol Education Program Adult Treatment Panel III deﬁnition modiﬁed for
age. Logistic regression was ﬁtted to estimate the association between vitamin D status and cardiometabolic risk
factors, adjusting for sex, parental education, BMI, physical activity and season.
Results:Mean (SD) vitamin D levels, 4.61 (2.50) μg for intake and 16.52 (5.72) ng/mL for serum, were below the
recommendations. The prevalence of MetS was 13.2%. Total cholesterol and LDL levels signiﬁcantly decreased
with 25(OH)D serum increase. After adjustment, no association was found between vitamin D levels and
MetS. Regarding MetS features, an increased odds of high BMI was observed for those with a lower intake (OR
1.87 95% CI 1.04–3.35).
Conclusions: Although a signiﬁcant increase in total and LDL cholesterol was observed for lower 25(OH)D levels,
and an increased odds of high BMI was observed for those with a lower vitamin D intake, no signiﬁcant associa-
tion was observed between vitamin D levels and metabolic syndrome.
© 2016 Elsevier Ireland Ltd. All rights reserved.Keywords:
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Adolescents1. Introduction
For decades, a great deal of attention to vitamin D has been placed on
understanding its role on bone health [1–3]. Vitamin D actions are medi-
ated through binding to a vitamin D receptor (VDR) located primarily in
the nuclei of target cells. The acknowledgement that VDR is found fairly
present in tissues not involved with calcium and phosphate
homeostasis suggests that vitamin D might play a more general role
than it was previously thought [4–6]. Furthermore, the increase from 5
to 10 μg proposed by the Institute of Medicine concerning theability and freedom from bias of
iversity of Porto, Ruadas Taipas,
.recommendations for adequate intake of vitamin D of Estimated
Average Requirement [7] highlights the growing conﬁdence of its rele-
vance for public health.
Recent studies have suggested that vitaminD levels play an important
role in cardiovascular diseases (CVDs) [8–11]. The mechanisms by which
vitamin Dmay be linked to CVDs involve the blunting effect of advanced
glycation end products on endothelial cells, which are related to arterial
stiffness and endothelial function [12,13]. Additionally, vitamin D may
also exert protective effects on the vessel walls by inhibition of macro-
phage to foam cell formation and via its anti-inﬂammatory effects [12,
13]. Also, vitamin D has been associated with the downregulation of the
renin-angiotensin-aldosterone system [12,13], with a lipid-lowering ef-
fect [14], decreased insulin resistance, increased insulin secretory re-
sponse to glucose and improved glucose homoeostasis [15].
CVDs remain the leading cause of death and disabilityworldwide [16].
Although these events occur most frequently during or after the ﬁfth de-
cade of life, longitudinal studies have shown that risk factors start in
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CVDs later in life [19].
The “obesogenic” environment that has been observed in themajor-
ity ofwestern societies during the last decades has contributed to the in-
crease in metabolic/physiologic changes at early ages [20]: raised blood
pressure (hypertension), overweight/obesity, impaired glucose and
raised blood lipids (dyslipidemia). The clustering of these risk factors
is called Metabolic Syndrome (MetS) [21]. Since these are the precur-
sors of CVD, it is of greater interest to measure the effect of vitamin D
in these risk factors at early stages [15].
Despite the emerging evidence suggesting an association between
low vitamin D levels and cardiometabolic risk factors [22,23], IOM re-
ports that available evidence is still insufﬁcient to link health beneﬁts
other than skeletal health to particular levels of vitamin D intake or
25(OH)D serummeasures [7]. One of the possible reasons for the differ-
ences between studies may lie in methodological differences regarding
themeasurement of exposure, once vitamin D can be obtained not only
through diet, but also through UVB exposure [6].
Even though studies have suggested an association between lower
vitamin D levels and the prevalence of MetS, few studies have explored
the effect of both dietary and serum vitamin D on cardiovascular risk
factors [24], and, to best of our knowledge, none has addressed the
period of adolescence.
The present study aimed to examine the association of vitamin D,
both intake and serum 25(OH)D levels, with cardiometabolic risk fac-
tors in 13-year-old adolescents.
2. Methods
Participants were adolescents from the Epidemiological Health
Investigation of Teenagers in Porto (EPITeen). As reported elsewhere
[25], the EPITeen evaluated adolescents born in 1990, who were
enrolled at public and private schools in Porto, Portugal, during the
2003/2004 school year. Data were collected using two self-
administered questionnaires: one fulﬁlled at home, comprising infor-
mation on demographic and social characteristics, family and individual
history of disease and a FFQ to evaluate food intake; and another ful-
ﬁlled at school, which included information on physical activity,
smoking and alcohol intake. A physical examination was performed at
school, by a team of experienced nurses, nutritionists and physicians,
comprising anthropometric assessment, blood pressure measurement
and a venous blood sample drawn after a 12-hour overnight fast.
The Ethics Committee of Hospital S. João approved the study and
written consent was obtained from both legal guardians and adolescents.
2.1. Participants
We identiﬁed 2786 eligible participants, of whom2159 agreed to par-
ticipate and provided information at least for part of the planned assess-
ment, resulting in an overall participation rate of 77.5%, similar in public
(77.7%) and private (77.0%) schools (p= 0.709).
Of the 2159 participants, 247 did not return the home questionnaire
and 297 did not ﬁll in the FFQ or were excluded because no information
was provided onmore than 10% of food items. A further 93 participants
were not considered for the current analysis because their total energy
intake was more than 3 times the interquartile range or their intake of
fruit or vegetables was more than 1.5 times the interquartile range. Ad-
ditionally, 80 participants did not perform the anthropometric or blood
pressure measurements; other 409 did not undergo blood collection.
Thus, the analysis on vitamin D intake was based on the information
of 1033 participants. For budgetary constraints, we evaluated serum vi-
tamin D levels for half of the samplewith intake information (n= 514).
Participants included in the analysis were compared to those not in-
cluded. Non included participants were mostly from public schools,
with less educated parents, and a higher proportion spent their time
on activities with higher level of physical activity. No signiﬁcantdifferences were found regarding sex, BMI and vitamin supplementa-
tion. Additionally, characteristics of participants from the subsample
(n = 514) were compared to those without serum vitamin D assess-
ment (n = 519). Participants with data on serum vitamin D presented
higher LDL cholesterol levels, lower insulin andHOMA levels, but no sig-
niﬁcant differenceswere observed regarding sex, vitaminD supplemen-
tation, BMI, waist circumference, total cholesterol, HDL cholesterol,
triglycerides and glucose.
2.2. Evaluation of vitamin D intake
Vitamin D intake was evaluated using a food frequency questionnaire
(FFQ) regarding the previous 12months, fulﬁlled by the adolescents with
the help of their parents or legal guardians. The FFQwas designed accord-
ing toWillett and colleagues [26] and adapted for the Portuguese popula-
tion, according to dietary data available for our country, and validated for
the adult population by comparison with four 7 daily food records (each
one in a different season of the year) [27]. The FFQ comprised a frequency
section with nine possible responses ranging from never to six or more
times daily. It was adapted for adolescents by including foods more fre-
quently eaten by this age group [28], comprising ninety-one food items
or beverage categories. It also included an open-ended section for foods
not listed in the questionnaire, but eaten at least once a week.
Seasonal variation of food consumptionwas also considered accord-
ing to participants' replies. To estimate nutrient intake,we used the soft-
ware Food Processor Plus® (ESHA Research, Salem, OR, USA) based on
values from the US Department of Agriculture. Values for Portuguese
food were added, based on the Portuguese tables of food composition,
typical recipes and data from previous studies [27].
Vitamin D supplements were not considered to quantify vitamin D
intake.
2.3. Evaluation of serum vitamin D
Serum 25(OH)Dwas determined using DiaSorin LIAISON®, which is
a direct competitive chemiluminescence immunoassay for human
serum or plasma intended for use on the DiaSorin LIAISON® automated
analyzer. The assay uses magnetic particles (solid phase) coated with
antibody against 25(OH)D and 25(OH)D conjugated to an isoluminol
derivative (tracer). During the ﬁrst incubation phase (10 min),
25(OH)D is dissociated from binding protein by buffer containing 10%
ethanol and then binds to the anti-25(OH)D antibody on the solid
phase. After a second 10 min incubation with the tracer, the unbound
material is washed off and starter reagents are added to generate a
ﬂash chemiluminescent signal which is measured by a photomultiplier
and is inversely related to 25(OH)D concentration [29].
2.4. Cardiometabolic risk factors
Weight and height were obtained with the subject in light indoor
clothes and no shoes. Weight was measured in kilograms, to the nearest
tenth, using a digital scale (Tanita TBF-300, Tanita Corporation of America,
Inc., Illinois, USA) and height was measured in centimeters, to the nearest
tenth, using a portable stadiometer. Adolescents were classiﬁed according
to the age- and sex-speciﬁc BMI based on the Centers for Disease Control
and Prevention's 2000 BMI-for-age growth charts for the United States
[30]. Based on this data we classiﬁed those above the 95th percentile as
obese and those between the 85th and 95th percentiles as overweight.
Waist circumference was measured to the nearest centimeter, mid-
way between the lower limit of the rib cage and the iliac crest, with the
subject standing, using a ﬂexible and non-distensible tape and avoiding
exertion of pressure on the tissues.
Blood pressure was measured with a mercury sphygmomanometer
using the auscultatory method, following the recommendations of the
AmericanAcademyof Pediatrics [31]. After 10min of rest, twobloodpres-
sure measurements were taken, separately by at least 5 min. A third
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than 5mmHg. The average of the two closestmeasurements was used in
this analysis. High blood pressure was considered if systolic or diastolic
blood pressure above the 90th percentile for age, sex, and height [31].
Serumglucose, cholesterol, triglycerides and high-density lipoprotein
(HDL)-cholesterol were determined using automatic standard routine
methods. Serum insulin was measured using a 125I-labelled insulin ra-
dioimmunoassay method. Insulin resistance was estimated according
to the homeostatic model assessment (HOMA), as the product of fasting
glucose (mmol/L) and insulin (μUI/mL) divided by a constant 22.5 [32].
Metabolic syndrome features was deﬁned according to the National
Cholesterol Education Program Adult Treatment Panel III deﬁnition
modiﬁed for age [33]: waist circumference ≥75th percentile [34] for
age and sex; HDL cholesterol b50mg/dL; triglycerides ≥100mg/dL; sys-
tolic or diastolic blood pressure ≥90th percentile for age, sex, and
height; and fasting glucose ≥110 mg/dL [31]. The presence of themeta-
bolic syndrome phenotype was deﬁned as having 3 or more of these 5
characteristics [33].
2.5. Covariates
Parental educational level was measured as the number of
successfully completed years of formal schooling and adolescentsTable 1
Vitamin D levels - intake (μg) and serum (ng/mL) - according to participants' characteristics.
Variable n % Vit D intake Me
(SD), μg/day
Overall 1033 4.61 (2.50)
Sex
Girls 554 53.6 4.51 (2.56)
Boys 479 46.4 4.72 (2.44)
Vitamin supplementation
No 779 73.0 4.52 (2.44)
Yes 205 27.0 5.00 (2.76)
Parental education (years)
0–6 240 23.5 4.63 (2.50)
7–9 218 21.3 4.80 (2.78)
10–12 281 27.5 4.60 (2.40)
N12 284 27.8 4.44 (2.40)
Physical activity
Mainly sitting 281 27.2 4.42 (2.34)
Mainly standing 234 22.7 4.60 (2.72)
Active 306 29.6 4.61 (2.39)
Very active 164 15.9 5.04 (2.67)
Season
March–July 643 62.2 4.46 (2.44)
November–February 390 37.8 4.85 (2.56)
BMI ≥95th percentilea
No 928 89.8 4.68 (2.55)
Yes 105 10.2 3.94 (1.94)
Waist circumference ≥75th percentilea
No 764 74.0 4.76 (2.62)
Yes 269 26.0 4.19 (2.10)
High blood pressureb
No 686 66.4 4.58 (2.38)
Yes 347 33.6 4.68 (2.74)
Fasting glucose ≥110 mg/dL
No 1027 99.4 4.62 (2.51)
Yes 6 0.6 3.94 (1.32)
HDL cholesterol b50 mg/dL
No 482 46.7 4.87 (2.72)
Yes 551 53.3 4.38 (2.27)
Triglycerides ≥100 mg/dL
No 914 88.5 4.58 (2.50)
Yes 119 11.5 4.82 (4.82)
Metabolic syndromec
No 897 86.8 4.64 (2.52)
Yes 136 13.2 4.38 (2.36)
a Data are according to age and sex.
b Deﬁned as systolic or diastolic blood pressure ≥ the 90th percentile for age, sex, and heigh
c Deﬁned according to the deﬁnition of de Ferranti et al. [33].were classiﬁed according to the parent with the highest educational
level.
Vitamin supplementation was assessed asking parents the question
“Did your child take supplements in the past 12months?”. If “yes” infor-
mationwas gathered on commercial name and dosage of supplementa-
tion. It was not possible to conﬁrm the composition for aminority of the
supplements reported (b5%), but for the supplements with information
a high dose of vitamin D was present. Thus, participants were classiﬁed
according towhether or not having taken supplements, without consid-
ering the speciﬁc dose, assuming that all participant with supplements
had high amount.
Leisure-time physical activity was classiﬁed according to a four-
choice question of subjective intensity categories (mainly sitting,
mainly standing, active or very active).
Season during which participants were evaluated was combined
into two categories: November–February and March–July.
2.6. Statistical analysis
Proportions were compared using the chi-square test or Fisher's
exact test, as appropriate. Quantitative variables were compared using
the student t-test and one-way ANOVA, the results being presented as
mean (standard deviation).an p n % Vit D serum Mean
(SD), ng/mL
p
514 16.52 (5.72)
0.164 270 52.5 15.71 (5.06) b0.001
244 47.5 17.76 (6.15)
0.016 382 74.3 16.52 (5.92) 0.685
112 21.8 16.77 (5.28)
0.484 94 18.3 16.71 (5.85) 0.014
89 17.3 14.78 (5.07)
148 28.8 16.72 (5.72)
183 35.6 17.11 (5.82)
0.085 149 29.0 16.46 (5.58) 0.061
103 20.0 15.86 (6.57)
162 31.5 16.34 (5.32)
73 14.2 18.15 (5.68)
0.016 343 66.7 17.24 (5.94) b0.001
171 33.3 15.09 (4.96)
0.004 466 90.7 16.45 (5.68) 0.370
48 9.3 17.23 (6.16)
0.001 374 72.8 16.70 (5.74) 0.252
140 27.2 16.05 (5.66)
0.536 345 67.1 16.63 (5.70) 0.550
169 32.9 16.31 (5.78)
0.512 511 99.4 16.53 (5.72) 0.874
3 0.6 16.00 (6.08)
0.002 245 47.7 16.15 (5.59) 0.159
269 52.3 16.86 (5.82)
0.317 462 89.9 16.65 (5.86) 0.151
52 10.1 15.44 (4.20)
0.263 454 88.3 16.57 (5.76) 0.642
60 11.7 16.20 (5.42)
t [31].
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and HOMA-IR) was performed, and means were then retransformed
to the original scale to improve data interpretation. Using linear regres-
sion models, crude and adjusted means and 95% conﬁdence intervals
(95% CI) of anthropometric andmetabolic characteristics were calculat-
ed according to quartiles of both vitamin D intake and serum levels.
Logistic regression models were ﬁtted to estimate odds ratio and 95%
CIs for the occurrence of selected cardiometabolic risk factors, according
to quartiles of both vitamin D intake and serum levels. All models were
further adjusted for sex, parental education, BMI, physical activity and
season.
Statistical signiﬁcance was considered with an alpha critical value of
0.05. Statistical analyses were performed using the Statistical Package
for the Social Sciences (IBM® SPSS® Statistics), version 21.0.3. Results
Table 1 presents the mean of vitamin D intake per day and serum
25(OH)D levels according to demographic and clinical characteristics
of the participants. The prevalence of metabolic syndrome was 13.2%.
The most prevalent MetS feature was low HDL cholesterol, with 53.3%
of participants showing values below 50mg/dL. In contrast, the compo-
nent with the lowest prevalence was high glucose levels (0.6% for both
sample and subsample).We observed very low levels of vitamin D from
both intake (4.61 (2.50) μg/day) and serum (16.52 (5.72) ng/mL). Vita-
min D intake was lower in those who reported not to use vitamin sup-
plements, in obese or abdominally obese, in those who had low HDL
cholesterol and in those who were evaluated between March and July.
Serum levels of vitamin D were lower in girls, in participants whoseTable 2
Mean (95% CI) of selected anthropometric and metabolic characteristics according to quartiles
Variable
Quartiles of vitamin D intake, μg/day
I (b2.88) II (2.88–4.10)
Anthropometrics
BMI 21.6 (21.1–22.1) 21.2 (20.8–21.6)
Waist circumference 73.5 (72.5–74.6) 72.9 (71.8–74.0)
Blood pressure, mm Hg
Systolic 113.3 (111.9–114.8) 113.8 (112.4–115.2
Diastolic 67.6 (66.6–68.6) 67.6 (66.6–68.5)
Lipids, mg/dL
Total cholesterol 166.7 (162.8–170.6) 165.5 (161.7–169.3
LDL cholesterol 105.3 (102.1–108.5) 103.7 (100.6–106.7
Triglycerides 61.6 (58.6–64.7) 59.2 (56.3–62.2)
HDL cholesterol 48.1 (46.7–49.5) 48.9 (47.6–50.2)
Diabetes-related measures
Fasting glucose, mg/dL 84.2 (83.0–85.3) 84.6 (83.5–85.8)
Fasting insulin, μU/mL 6.2 (5.6–7.0) 6.2 (5.6–7.0)
Homa–IR 1.2 (1.2–1.4) 1.3 (1.2–1.4)
Quartiles of serum vitamin D, ng/mL
I (b13.0) II (13.0–16.0)
Anthropometrics
BMI 21.3 (20.8–21.8) 21.0 (20.4–21.6)
Waist circumference 73.3 (72.0–74.6) 72.3 (70.7–73.8)
Blood pressure, mm Hg
Systolic 113.7 (112.0–115.4) 113.4 (111.3–115.5
Diastolic 68.2 (66.8–69.8) 68.2 (66.8–69.8)
Lipids, mg/dL
Total cholesterol 172.2 (167.7–176.8) 166.0 (160.2–171.8
LDL cholesterol 109.8 (106.1–113.4) 104.0 (99.4–108.7)
Triglycerides 61.0 (57.7–64.6) 61.5 (57.2–66.1)
HDL cholesterol 49.4 (47.7–51.0) 48.2 (46.2–50.4)
Diabetes-related measures
Fasting glucose, mg/dL 83.9 (82.6–85.3) 84.5 (82.8–86.3)
Fasting insulin, μU/mL 6.2(5.5–7.1) 6.4(5.4–7.4)
Homa–IR 1.2(1.1–1.4) 1.3(1.1–1.5)parents presented a lower educational level and in those who were
evaluated between November and February.
The crudemean (95% CI) of cardiometabolic risk factors according to
quartiles of vitamin D levels is shown in Table 2. Decreasing levels of
BMI and waist circumference were observed with vitamin D intake in-
crease. Regarding serum vitamin D, decreasing values of total cholester-
ol, LDL and triglycerides were foundwith increasing levels of vitamin D,
the same trend was found for systolic and diastolic blood pressure
levels, but not reaching statistical signiﬁcance. After adjusting for sex,
parental education, BMI, physical activity and season, no signiﬁcant dif-
ferences were observed for all of the features concerning intake of vita-
min D, but the decrease on total and LDL cholesterol levels with
increasing serum vitamin D levels remained signiﬁcant (Table 3).
Considering the occurrence of MetS and its features, no association
was observed with vitamin D levels, however, we found a higher odds
of high adiposity among thosewith lower vitamin D intake and a higher
odds of higher triglycerides among those with lower serum vitamin D
levels (Table 4).4. Discussion
In this sample we found very low levels of vitamin D intake (4.61
(2.50) μg/day) and 25(OH)D (16.52 (5.72) ng/mL), reinforcing the de-
scriptions of the worldwide high prevalence of vitamin D deﬁciency
[35–37], also observed in adolescents from other European countries
[38–40]. Despite the low vitamin D levels found, a signiﬁcant increase
of total and LDL cholesterol and triglycerides was observed among
those with lower levels of serum vitamin D. Moreover, an increased
odds of high BMI was observed for those with a lower intake.of vitamin D (intake and serum).
III (4.11–5.60) IV (N5.60) P-trend
20.9 (20.5–21.3) 20.7 (20.3–21.1) 0.023
72.8 (71.7–73.9) 71.6 (70.7–72.6) 0.088
) 112.1 (110.8–113.4) 112.6 (111.2–114.0) 0.301
68.0 (66.9–69.1) 68.3 (67.4–69.3) 0.680
) 166.9 (163.0–170.8) 165.7 (161.9–169.4) 0.940
) 103.6 (100.6–106.6) 103.4 (100.4–106.4) 0.827
58.4 (55.6–61.4) 60.2 (57.2–63.2) 0.506
50.6 (49.2–52.0) 49.1 (47.6–50.6) 0.088
85.3 (84.1–86.5) 86.1 (84.9–87.3) 0.113
6.4 (5.7–7.1) 6.1 (5.4–6.8) 0.961
1.3(1.2–1.4) 1.2 (1.2–1.4) 0.972
III (17.0–20.0) IV (N20.0) P-trend
20.7 (20.0–21.3) 21.1 (20.0–21.3) 0.557
72.3 (70.8–73.8) 72.8 (71.2–74.2) 0.708
) 112.4 (110.4–114.4) 111.3 (109.3–113.4) 0.309
67.5 (66.0–69.0) 67.0 (65.6–68.4) 0.566
) 169.8 (164.2–175.4) 157.8 (152.2–163.3) 0.001
106.4 (102.0–111.0) 98.4 (93.8–102.8) 0.002
57.1 (53.2–61.2) 54.0 (50.4–57.8) 0.022
51.2 (49.2–53.3) 47.8 (45.8–49.9) 0.099
85.9 (84.2–87.6) 84.5 (82.8–86.2) 0.356
5.8(5.0–6.8) 5.4(4.6–6.3) 0.437
1.2(1.0–1.4) 1.1(1.0–1.3) 0.540
Table 3
Adjusted mean (95% CI) of selected anthropometric and metabolic characteristics according to quartiles of vitamin D (intake and serum).
Variable
Quartiles of vitamin D intake, μg/day
I (b2.88) II (2.88–4.10) III (4.11–5.60) IV (N5.60) P-trend
Anthropometrics
BMIa 21.4 (21.0–21.9) 21.1 (20.6–21.6) 20.8 (20.4–21.2) 20.6 (20.2–21.0) 0.078
Waist circumferencea 73.4 (72.3–74.5) 73.0 (71.8–74.0) 72.6 (71.6–73.8) 71.5 (70.4–72.6) 0.081
Blood Pressure, mm Hg
Systolicb 113.3 (112.0–114.6) 114.1 (112.8–115.4) 112.7 (111.4–114.0) 113.2 (112.0–114.6) 0.528
Diastolicb 67.0 (66.0–68.0) 67.1 (66.1–68.2) 68.1 (67.2–69.2) 68.4 (67.4–69.4) 0.104
Lipids, mg/dL
Total cholesterolb 167.5 (163.6–171.4) 166.1 (162.2–170.0) 167.6 (163.8–171.6) 165.9 (162.0–169.7) 0.883
LDL cholesterolb 104.8 (101.6–108.2) 103.4 (100.2–106.6) 103.5 (100.4–106.7) 103.5 (100.4–106.6) 0.904
Triglyceridesb 61.0 (58.0–64.0) 58.6 (55.7–61.6) 59.1 (56.2–62.2) 60.3 (56.8–62.8) 0.688
HDL cholesterolb 49.4 (48.0–50.8) 49.9 (48.6–51.2) 51.2 (49.8–52.6) 49.2 (47.9–50.6) 0.169
Diabetes-related measures
Fasting glucose, mg/dLb 84.2 (82.9–85.4) 85.0 (83.8–86.2) 85.7 (84.5–86.9) 86.0 (84.9–87.2) 0.132
Fasting insulin, μU/mLb 6.0 (5.4–6.8) 6.4 (5.6–7.0) 6.6 (6.0–7.4) 6.4 (5.6–7.0) 0.696
Homa –IRb 1.2 (1.1–1.4) 1.3 (1.2–1.4) 1.4 (1.2–1.6) 1.3 (1.2–1.5) 0.559
Quartiles of serum vitamin D, ng/mL
I (b13.0) II (13.0–16.0) III (17.0–20.0) IV (N20.0) P-trend
Anthropometrics
BMIa 21.1 (20.6–21.6) 21.1 (20.4–21.8) 20.6 (20.0–21.3) 21.2 (20.5–21.8) 0.662
Waist circumferencea 73.1 (71.8–74.4) 72.7 (71.1–74.4) 72.3 (70.7–73.9) 72.7 (71.0–74.3) 0.885
Blood Pressure, mm Hg
Systolicb 113.8 (112.2–115.5) 113.7 (111.6–115.8) 112.7 (110.7–114.7) 111.3 (109.2–113.4) 0.224
Diastolicb 67.4 (66.2–68.7) 67.7 (66.2–69.2) 66.8 (65.4–68.4) 66.3 (64.8–67.8) 0.516
Lipids, mg/dL
Total cholesterolb 172.6 (167.7–177.5) 167.0 (161.0–173.0) 169.3 (163.4–175.2) 158.6 (153.0–164.5) 0.003
LDL cholesterolb 109.4 (105.5–113.4) 103.7 (98.8–108.6) 105.3 (100.6–110.1) 97.9 (93.0–102.8) 0.003
Triglyceridesb 59.1 (55.7–62.8) 57.6 (57.9–66.7) 56.8 (53.0–60.9) 54.6 (50.4–59.1) 0.067
HDL cholesterolb 50.2 (48.6–52.0) 49.6 (47.4–51.6) 52.0 (49.9–54.0) 49.0 (46.9–51.0) 0.179
Diabetes-related measures
Fasting glucose, mg/dLb 84.6 (83.0–86.0) 85.4 (83.5–87.2) 86.0 (84.2–87.8) 85.2 (83.4–87.0) 0.642
Fasting insulin, μU/mLb 6.0 (5.4–7.0) 6.6 (5.6–7.8) 6.0 (5.2–7.1) 5.9 (5.0–6.8) 0.706
Homa –IRb 1.2 (1.1–1.4) 1.4 (1.2–1.6) 1.2 (1.0–1.5) 1.2 (1.0–1.4) 0.736
a Adjusted for sex, parental education, physical activity and season.
b Adjusted for sex, parental education, BMI, physical activity and season.
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cant, our results show that those with lower vitamin D levels present
a worse cardiometabolic proﬁle. A possible reason for this lack of signif-
icant association might be due to the low vitamin D levels observed
among participants that might have smoothed out differences, since
not even the reference class presented desirable values.
A greater odds was observed for obesity among adolescents with
lower vitamin D intake. The same trend was also observed for serum
25(OH)D levels, but without reaching statistical signiﬁcance. Despite
having been often suggested the sequestration within adipose tissue
as an explanation for the lower levels of vitamin D in subjects with a
higher BMI [41,42], our results indicate that the lower vitamin D intake
by these individuals should also be considered.
Our results showedno relationship between cholesterol and vitamin
D intake, however, when considering serum 25(OH)D levels, cholester-
ol levels increased with vitamin D decrease. Although the relationship
between vitamin D intake and cardiovascular outcomes is less studied,
these results are in accordance with previous studies, in which the rela-
tionship between vitamin D intake and cardiometabolic risk factors was
less robust than comparing to serum 25(OH)D levels [24]. The
mechanism that can explain the relationship between vitamin D and
cholesterol is not yet clariﬁed, nevertheless, it has been suggested that
through an increased calcium level, vitamin D may reduce hepatic tri-
glyceride formation and/or secretion, and, also, that it can inﬂuence
lipid metabolism through the effect on both insulin secretion and insu-
lin sensitivity [43].
Studies have suggested that vitamin D may be a negative endocrine
regulator of the renin-angiotensin system, through the inhibition of the
renin gene expression by the activated metabolite of 25(OH)D, 1,25-
dihydroxyvitamin D (1,25[OH]2D) [44]. However, in the present studyno association was found between low vitamin D levels (intake and
serum) and high blood pressure. A systematic review conducted in
2010, which evaluated 13 observational studies and 18 randomized tri-
als veriﬁed that while in a meta-analysis of 3 cohorts, lower 25(OH)D
concentration was associated with incident hypertension, in another
meta-analysis of 10 trials, the supplementation with vitamin D did not
signiﬁcantly reduce blood pressure, concluding that the association be-
tween vitamin D deﬁciency and hypertension is not ﬁrmly established
[45].
No differences were also observed between quartiles of vitamin D
and glucose, insulin and, consequently, HOMA, possibly due to the
lower prevalence of these features which may prevent the effect to be
estimated.
In general, no association was found regarding vitamin D intake,
which could be explained by measurement errors. The fact that the
FFQ was not speciﬁcally designed for assessing vitamin D intake might
be considered a restraint of the study, however, the main sources of vi-
tamin D intake (e.g. fatty ﬁsh, milk, eggs) were speciﬁcally asked. Addi-
tionally, the FFQ was designed for the Portuguese population [27] and
foods or food groups eatenmore frequently by adolescents were includ-
ed in the questionnaire. Also, adolescents were encouraged to list foods
eaten at least once weekly not enumerated in the FFQ, in an open sec-
tion. Vitamin D supplementation was not considered to the estimative
of vitamin D intake, which may have contributed to the low vitamin D
intake observed. However, since vitamin supplementation was signiﬁ-
cantly higher in participants with higher vitamin D intake, it indicates
that the association between intake and MetS features would not have
been affected.
Besides the low vitamin D intake observed, serum 25(OH)D concen-
trations were also very low. This is consistent with the high prevalence
Table 4
Adjusted odds ratios (95% CI) of selected cardiometabolic risk factors according to vitamin D levels (intake and serum).
Quartiles of Vitamin D intake, μg
Variable I (b2.88) II (2.88–4.10) III (4.11–5.60) IV (N5.60)
BMI ≥ 95th percentilea
Prevalence, % 15.2 8.9 8.1 8.5
Adjusted ORb 1.87 (1.04–3.35) 1.08 (0.58–2.04) 0.99 (0.52–1.90) 1.00 (reference)
Waist circumference ≥ 75th percentile
Prevalence, % 30.0 27.5 25.5 21.2
Adjusted ORc 1.02 (0.50–2.06) 1.30 (0.65–2.57) 1.32 (0.67–2.60) 1.00 (reference)
High blood pressured
Prevalence, % 35.0 32.9 32.8 33.6
Adjusted ORc 0.96 (0.64–1.42) 0.93 (0.62–1.38) 1.00 (0.67–1.48) 1.00 (reference)
Fasting glucose ≥ 110 mg/dL†
Prevalence, % 0.8 0.4 0.8 0.4
HDL cholesterol b 50 mg/dL
Prevalence, % 59.1 55.0 47.9 51.4
Adjusted ORc 1.22 (0.84–1.78) 1.07 (0.74–1.55) 0.84 (0.58–1.22) 1.00 (reference)
Triglycerides ≥ 110 mg/dL
Prevalence, % 12.1 8.9 10.4 14.7
Adjusted ORc 0.76 (0.44–1.32) 0.49 (0.27–0.89) 0.75 (0.43–1.32) 1.00 (reference)
Metabolic syndromee
Prevalence, % 16.0 12.4 10.8 13.5
Adjusted ORc 0.82 (0.43–1.54) 0.66 (0.34–1.28) 0.66 (0.33–1.32) 1.00 (reference)
Quartiles of serum vitamin D, ng/mL
I (b13.0) II (13.0–16.0) III (17.0–20.0) IV (N20.0)
BMI ≥ 95th percentilea
Prevalence, % 8.6 9.3 9.6 10.3
Adjusted ORb 0.64 (0.26–1.54) 0.84 (0.32–2.14) 0.82 (0.32–2.10) 1.00 (reference)
Waist circumference ≥ 75th percentile
Prevalence, % 29.9 25.0 27.8 24.8
Adjusted ORc 1.26 (0.48–3.29) 1.03 (0.36–2.89) 1.64 (0.58–4.50) 1.00 (reference)
High blood pressured
Prevalence, % 33.3 36.1 32.2 29.9
Adjusted ORc 1.08 (0.62–1.90) 1.29 (0.70–2.36) 1.06 (0.58–1.96) 1.00 (reference)
Fasting glucose ≥ 110 mg/dL†
Prevalence, % 1.1 0 0 0.9
HDL cholesterol b 50 mg/dL
Prevalence, % 49.4 53.7 51.3 56.4
Adjusted ORc 0.84 (0.50–1.42) 0.96 (0.54–1.70) 0.90 (0.51–1.59) 1.00 (reference)
Triglycerides ≥ 110 mg/dL
Prevalence, % 9.2 19.4 7.0 6.0
Adjusted ORc 1.74 (0.63–4.75) 4.91 (1.84–13.10) 1.17 (0.37–3.68) 1.00 (reference)
Metabolic syndromee
Prevalence, % 10.9 15.7 10.4 10.3
Adjusted ORc 1.13 (0.44–2.93) 1.97 (0.74–5.22) 0.88 (0.30–2.53) 1.00 (reference)
a BMI classiﬁed according to age and sex [33].
b Adjusted for sex, parental education, physical activity and season.
c Adjusted for sex, parental education, physical activity, BMI and season.
d Deﬁned as systolic or diastolic blood pressure ≥ the 90th percentile for age, sex, and height [31].
e Insufﬁcient cases to measure the association.
† Deﬁned according to the deﬁnition of de Ferranti et al. [33].
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tion for the low serum levels observed could be the time of storage,
since all blood samples were stored after collection and analyzed
≈10 years after. However, participants evaluated during the winter
season (November–February) presented lower levels of vitamin D. In
fact, in the northern hemisphere at latitudes N40°N (latitude of Porto
where the study was conducted) sunlight appears not to be strong
enough to trigger cutaneous synthesis from November to February
[38,46]. This supports that the loss in storage is non differential, there-
fore, the association between serum25(OH)D levels and the cardiomet-
abolic risk factors is also not expected to be affected.
Notwithstanding the above limitations, this study is, to the best of
our knowledge, the ﬁrst examining the association between vitamin D
levels, both intake and serum 25(OH)D, with cardiometabolic risk fac-
tors in adolescents. Moreover, the dataset employed was from a
population-based sample, whichmay enhance generalizability. Howev-
er, because data are cross-sectional, the causative nature of associations
cannot be determined, yet, it is not expected that participants havealtered their behaviour in consequence of the features evaluated. There-
fore, we can assume that the relationship veriﬁed is not the result of re-
verse causality.
5. Conclusion
Although, in general, no signiﬁcant associations were found, a trend
for increasing levels of cardiometabolic risk factorswas veriﬁedwith de-
creasing vitamin D levels. The effect was stronger for serum than for in-
take levels, possibly because serum 25(OH)D levels reﬂect vitamin D
from both intake and cutaneous synthesis. The low levels observed for
both vitamin D intake and serum 25(OH)D levels, and the reduced var-
iability of exposure may have limited the ability to detect a possible as-
sociation with the cardiometabolic risk factors.
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